- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02267993
Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients
A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this single-center, randomized, open-label, crossover, prospective clinical trial, a total of 120 AML patients who achieved remission following induction chemotherapy will be recruited and randomized into two groups, of 60 cases in each group. For one group, the treatment cycle is in the first chemotherapy cycle and the control cycle is in the second one. For another group, the treatment cycle is in the second chemotherapy cycle and the control cycle is in the first one.
Each subject is required to undergo two cycles of chemotherapy. At the treatment cycle, patients received subcutaneous injection of rhTPO at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and rhTPO treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused. At the control cycle, rhTPO therapy is not given.
Each subject is required to be followed up for successive two chemotherapy cycles following inclusion in this study. During the follow-up period, routine blood test is performed once every other day, and platelet transfusion is recorded.
The safety of rhTPO is evaluated by the monitoring of liver and renal functions, blood coagulation, and TPO-neutralizing antibody, and adverse events associated with rhTPO treatment are recorded during the study period.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Institute of Hematology & Blood Diseases Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 18-55 years;
- Patients that meet the diagnostic criteria of acute myeloid leukemia (except M3 and M7 subtypes), and achieve complete remission following induction chemotherapy and undergo consolidation therapy;
- Patients who require two successive cycles of DA (Ara-c 1.5 g/m2/q12 h and DNR 40 mg/m2/d on days 1-3) or MA regimen (Ara-C 1.5 g/m2/q12 h and MTZ 6 mg/m2/d on days 1-3) at the phase of consolidation therapy, or underwent consolidation therapy with administration of Ara-C 3 g/m2/q12 h alone, with dose adjustment of less than 10% Ara-C dose;
- Patients with the minimum platelet count of < 30´109/L at the final cycle of chemotherapy during the induction stage;
- Patients without apparent liver or renal dysfunctions (serum levels of urea nitrogen, creatinine, aminotransferase and bilirubin were all ≤ 1.5 times of the normal upper limit);
- Patients without severe heart or lung dysfunctions;
- Patients with life expectancy of > 12 weeks;
- Patients with ECOG score of ≤ 2;
- Patients are willing to participate in the study and sign the informed consent.
Exclusion Criteria:
- Patients with a medical history of severe allergy to biologics;
- Patients with thromboembolic or hemorrhagic disease, or a recent medical history of thrombosis;
- Patients with a history of mental disorders;
- Pregnant or lactating patients, or patients with failure in use of contraception during the study period;
- Patients with M3 or M7 subtype;
- Patients with a platelet count of 1000 ´109/L at the start of the study;
- Patients with other factors which were considered not to be suitable to participate in the study by the investigators.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A
At the first chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
At the second chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given.
|
Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
Other Names:
|
Experimental: Arm B
At the first chemotherapy cycle (control cycle), recombinant human thrombopoietin therapy is not given; at the second chemotherapy cycle (treatment cycle), patients receive recombinant human thrombopoietin treatment.
|
Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of platelet count of < 20 ´ 109/Lat each cycle of chemotherapy.
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time and dose of platelet transfusion at each cycle of chemotherapy
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
The minimum platelet count at each cycle of chemotherapy
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
Duration from the minimum platelet count to ≥ 20´109/L at each cycle of chemotherapy according to CTCAE(v4.0)
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
Number and grade of bleeding Adverse Events at each cycle of chemotherapy
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
Duration of hospital stay (from the first day of chemotherapy to discharge from hospital) at each cycle of chemotherapy
Time Frame: From Day1 after chemotherapy up to Day21 after chemotherapy
|
From Day1 after chemotherapy up to Day21 after chemotherapy
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IHBDH-IIT2014010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombocytopenia
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Central Hospital, Nancy, FranceRecruitingHeparin-induced ThrombocytopeniaFrance
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingHeparin-induced Thrombocytopenia
-
University of ArizonaAmerican College of Clinical PharmacyRecruitingHeparin-induced ThrombocytopeniaUnited States
-
Veralox TherapeuticsCelerionCompletedHeparin-induced ThrombocytopeniaUnited States
-
Aspen Global IncorporatedTerminatedHeparin-induced ThrombocytopeniaUnited States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
-
Marshall UniversityUnknownHeparin-induced ThrombocytopeniaUnited States
-
Napolitano MariasantaRegione SiciliaTerminatedThrombocytopenia | Primary Thrombocytopenia,Unspecified | Thrombocytopenia Chemotherapy InducedItaly
-
Ottawa Hospital Research InstituteUnknownHeparin-induced Thrombocytopenia (HIT)Canada
Clinical Trials on recombinant human thrombopoietin
-
Shandong UniversityShandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...CompletedImmune ThrombocytopeniaChina
-
Tianjin Medical University General HospitalUnknown
-
Peking Union Medical CollegeShenyang Sunshine Pharmaceutical Co., LTD.UnknownThrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic PurpuraChina
-
Hongnan MoUnknownHematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell MobilizationChina
-
Shenyang Sunshine Pharmaceutical Co., LTD.Unknown
-
Nanfang Hospital of Southern Medical UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaboratorsUnknownAllogeneic Hematopoietic Stem Cell Transplantation | Myeloablative | Delayed Platelet EngraftmentChina
-
Chinese Society of Lung CancerTerminatedCarcinoma, Non-Small-Cell LungChina
-
Nanfang Hospital of Southern Medical UniversityThe Third Affiliated Hospital of Southern Medical University; The Second People... and other collaboratorsNot yet recruitingPneumonia | Thrombocytopenia
-
First Affiliated Hospital Xi'an Jiaotong UniversityShenyang Pharmaceutical UniversityUnknown
-
Peking University People's HospitalUnknownCorticosteroid-resistant or Relapsed ITPChina